Yildiray Yildiz, Veysel Bayburtluoglu, Eda Tokat, Ali K Yildiz, Aykut Ucar, Sebnem Erdinc, Omer G Doluoglu
{"title":"COVID-19患者前列腺特异性抗原值的变化","authors":"Yildiray Yildiz, Veysel Bayburtluoglu, Eda Tokat, Ali K Yildiz, Aykut Ucar, Sebnem Erdinc, Omer G Doluoglu","doi":"10.24875/CIRU.22000479","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate changes in prostate-specific antigen (PSA) values in patients with coronavirus disease 2019 (COVID-19).</p><p><strong>Method: </strong>Male patients who were admitted to our flu outpatient clinic with cough, fever, weakness, and bone and joint pain were evaluated. The acute phase reactants of erythrocyte sedimentation rate, C-reactive protein, ferritin, and fibrinogen were measured both at the time the patients first presented at the clinic and 1 month after recovery from COVID-19 infection. PSA and free PSA were also measured at the same time. The difference in acute phase reactants and PSA values during active COVID-19 infection and after recovery was assessed using the paired samples t-test.</p><p><strong>Results: </strong>The mean PSA values of the patients were 2.73 ± 3.7 μg/L in the period of active infection, and 2.04 ± 2.32 μg/L 1 month later (p = 0.12). In the 29 patients with PSA values in the gray zone, the PSA values were determined as 6.6 ± 4.4 μg/L during infection and 4.1 ± 2.9 μg/L after treatment (p = 0.001).</p><p><strong>Conclusion: </strong>The results of this study showed that PSA values in the gray zone during COVID-19 infection decreased after treatment when the patient recovered.</p>","PeriodicalId":93936,"journal":{"name":"Cirugia y cirujanos","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Changes in prostate specific antigen value in patients with COVID-19.\",\"authors\":\"Yildiray Yildiz, Veysel Bayburtluoglu, Eda Tokat, Ali K Yildiz, Aykut Ucar, Sebnem Erdinc, Omer G Doluoglu\",\"doi\":\"10.24875/CIRU.22000479\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>To evaluate changes in prostate-specific antigen (PSA) values in patients with coronavirus disease 2019 (COVID-19).</p><p><strong>Method: </strong>Male patients who were admitted to our flu outpatient clinic with cough, fever, weakness, and bone and joint pain were evaluated. The acute phase reactants of erythrocyte sedimentation rate, C-reactive protein, ferritin, and fibrinogen were measured both at the time the patients first presented at the clinic and 1 month after recovery from COVID-19 infection. PSA and free PSA were also measured at the same time. The difference in acute phase reactants and PSA values during active COVID-19 infection and after recovery was assessed using the paired samples t-test.</p><p><strong>Results: </strong>The mean PSA values of the patients were 2.73 ± 3.7 μg/L in the period of active infection, and 2.04 ± 2.32 μg/L 1 month later (p = 0.12). In the 29 patients with PSA values in the gray zone, the PSA values were determined as 6.6 ± 4.4 μg/L during infection and 4.1 ± 2.9 μg/L after treatment (p = 0.001).</p><p><strong>Conclusion: </strong>The results of this study showed that PSA values in the gray zone during COVID-19 infection decreased after treatment when the patient recovered.</p>\",\"PeriodicalId\":93936,\"journal\":{\"name\":\"Cirugia y cirujanos\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cirugia y cirujanos\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.24875/CIRU.22000479\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cirugia y cirujanos","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24875/CIRU.22000479","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Changes in prostate specific antigen value in patients with COVID-19.
Objectives: To evaluate changes in prostate-specific antigen (PSA) values in patients with coronavirus disease 2019 (COVID-19).
Method: Male patients who were admitted to our flu outpatient clinic with cough, fever, weakness, and bone and joint pain were evaluated. The acute phase reactants of erythrocyte sedimentation rate, C-reactive protein, ferritin, and fibrinogen were measured both at the time the patients first presented at the clinic and 1 month after recovery from COVID-19 infection. PSA and free PSA were also measured at the same time. The difference in acute phase reactants and PSA values during active COVID-19 infection and after recovery was assessed using the paired samples t-test.
Results: The mean PSA values of the patients were 2.73 ± 3.7 μg/L in the period of active infection, and 2.04 ± 2.32 μg/L 1 month later (p = 0.12). In the 29 patients with PSA values in the gray zone, the PSA values were determined as 6.6 ± 4.4 μg/L during infection and 4.1 ± 2.9 μg/L after treatment (p = 0.001).
Conclusion: The results of this study showed that PSA values in the gray zone during COVID-19 infection decreased after treatment when the patient recovered.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
